CRISPR Therapeutics to Unveil Phase 1 Data for Autoimmune CAR-T Therapy at ACR 2026
Event summary
- CRISPR Therapeutics will present Phase 1 clinical data for zugocabtagene geleucel (zugo-cel) in refractory systemic sclerosis at ACR Convergence 2026 on November 8, 2026.
- Zugo-cel is a CRISPR/Cas9 gene-edited allogeneic CAR-T therapy targeting CD19 for autoimmune diseases.
- The therapy is being evaluated in Phase 1 trials across multiple autoimmune indications, including rheumatologic, hematologic, and neurologic diseases.
- CRISPR Therapeutics previously achieved a historic milestone with the approval of CASGEVY®, the world’s first CRISPR-based therapy.
The big picture
CRISPR Therapeutics is expanding its footprint beyond hemoglobinopathies into autoimmune diseases with zugocabtagene geleucel, leveraging its CRISPR/Cas9 gene-editing expertise. The presentation at ACR Convergence 2026 comes at a critical juncture as the company seeks to validate its technology in new therapeutic areas, following the success of CASGEVY®. The strategic collaboration with Vertex Pharmaceuticals further underscores the company’s commitment to broadening its pipeline and commercial potential.
What we're watching
- Clinical Efficacy
- How the Phase 1 data for zugocabtagene geleucel will impact the therapeutic potential of CRISPR/Cas9 gene-edited CAR-T therapies in autoimmune diseases.
- Regulatory Pathway
- Whether the positive data will accelerate regulatory approvals for zugocabtagene geleucel in multiple autoimmune indications.
- Pipeline Expansion
- The pace at which CRISPR Therapeutics can advance its diversified pipeline, including its SyNTase™ editing platform and collaborations with Vertex Pharmaceuticals.
Related topics